ClinicalTrials.gg
WithdrawnNCT05033132Updated Mar 28, 2024

A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

A Phase 2 interventional study of Balstilimab and Balstilimab + Zalifrelimab in Cervical Cancer, sponsored by Agenus Inc.. Withdrawn at 43 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Agenus Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study was never initiated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Enrollment
356th of 360
0 · median 90
Started
2021
with 51 others
Phase 2
137 of 455
71 open now
Registered
191st of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 356th largest by enrollment of the 360 interventional ones that give a count, is one of 52 that started in 2021, is one of 137 in phase 2, and was the 191st registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multi-center Phase II clinical trial to assess the efficacy, safety, and pharmacokinetics of Balstilimab (Treatment Arm 1 - monotherapy) or in combination with Zalifrelimab (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy.

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily agree to participate by giving written .
  • Diagnosis:

    1. Have a or cytologically confirmed, locally advanced, inoperable and/or cervical squamous cell carcinoma, cervical adenosquamous cell carcinoma or cervical adenocarcinoma. Note: A pathological report confirmed by histology or cytology of the primary tumor is required for definitive diagnosis. The following cervical tumors are not eligible for inclusion: minimal deviation adenocarcinoma, gastric-type endocervical adenocarcinoma, clear cell adenocarcinoma of the cervix, neuroendocrine carcinoma of the cervix and mesonephric adenocarcinoma.
    2. Patients with recurrent/metastatic cervical cancer who have received at least 1 platinum-based systemic therapy (excluding radiosensitizing chemotherapy) (with or without bevacizumab), and experienced recurrence or progression of cervical cancer or were intolerable to chemotherapy toxicity during or after the systemic therapy and were unable to receive radiotherapy or radical surgery again. Note (definition of failure or intolerability of platinum-based chemotherapy):

      1. Patients with recurrent or metastatic cervical cancer who have experienced disease progression during platinum-based regimen or have experienced disease progression after receiving ≥4 cycles of effective platinum-based regimen (complete response/progressive disease/stable disease) or were intolerable to toxicity caused by platinum during/after platinum-based regimen and were not suitable for continuous platinum-based regimen.

        Or

      2. Patients with cervical cancer progressed or during or adjuvant chemotherapy with platinum-based regimen (≥4 cycles if the platinum-based regimen is effective) or within 6 months after the end of the treatment, are deemed to have failed first-line platinum-based chemotherapy.
    3. Programmed death-ligand 1 () positive (combined positive score ≥1).
  • Have at least 1 on imaging based on 1.1. Measurable lesions should have not been treated with topical treatment such as radiotherapy. If the only one measurable lesion has been treated with previous topical treatment (radiotherapy, ablation, vascular intervention, etc.), it is necessary to confirm that the lesion has progressed, otherwise it will be recorded as a non-target lesion.
  • Have a of at least 3 months.
  • performance status of 0 or 1.
  • Have satisfactory organ function as indicated by the following laboratory values:

    1. Bone marrow: >1.5 × 10\^9/liter (L), count >100 × 10\^9/L, and >8 grams (g)/deciliter (80 g/deciliter) (without transfusions of blood or blood component within 2 weeks of test);
    2. Liver: serum total (TBIL) level ≤1.5 × (ULN), (AST) level ≤2.5 × ULN, alanine aminotransferase (ALT) level ≤2.5 × ULN (TBIL ≤1.5 × ULN, AST ≤5 × ULN, ALT ≤5 × ULN in case of presence of liver metastases);
    3. Serum creatinine ≤1.5 × ULN; or endogenous ≥50 milliliters/minute for serum creatinine >1.5 × ULN;
    4. Eligible coagulation function, defined as and prothrombin time ≤1.5 x institutional upper limit of normal (IULN); and activated partial thromboplastin time ≤1.5 x IULN.
  • No history of other within 5 years prior to first dose, except for basal cell carcinoma of the skin, superficial bladder cancer, and squamous cell carcinoma of the skin.
  • Patient must provide an adequate amount of eligible formalin fixed paraffin-embedded tumor tissue samples, preferably from a recent tumor focus , or tumor tissue samples collected at or after the diagnosis of advanced or metastatic tumors from the site that has not been previously treated with radiation. If tumor tissue is not available, a tumor biopsy is required.
  • Female patients with or without , for the former, the serum pregnancy test should be negative at the time of screening (serum pregnancy test is preferred within 7 days prior to first dose of the drug, otherwise urine pregnancy test is acceptable if serum pregnancy test is not available). Female patients without childbearing potential are defined as follows (for reasons other than medication): ≥45 years of age and menopause for more than 1 year; post hysterectomy, post oophorectomy or post tubal ligation.
  • Females of potential pregnancy must use a highly effective method of (e.g., oral contraceptives, intrauterine devices, abstinence or barrier contraception combined with spermicide) throughout the study and continue contraception for 12 months after the end of treatment.
  • Is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  • Is currently participating and receiving study therapy or has participated in a study of an agent and received study therapy or used an investigation device within 4 weeks of the first dose of treatment.
  • Has an inadequate prior to first dose of study drug defined as: received systemic cytotoxic chemotherapy or biological therapy within 3 weeks before first dose; received radiation therapy within 3 weeks before first dose; experienced major surgical procedures within 4 weeks prior to the first dose.
  • Has received prior therapy with any antibody/drug-targeting T-cell co-stimulatory proteins (immune checkpoints), including but not limited to , PD-L1, CTLA-4, lymphocyte-activation gene 3, therapeutic vaccines, etc.
  • Have not recovered from the toxicity of their last systemic antineoplastic therapy to grade 1 or below as defined by National Cancer Institute - (NCI-CTCAE) 5.0 prior to the first dose of the study. Note: Patients with sensory neuropathy or alopecia grade ≤2 are eligible.
  • Is expected to require any other form of systemic or localized antineoplastic therapy while on trial (including maintenance therapy with another agent, radiation therapy, and/or surgical resection).
  • Has known severe reactions to fully human monoclonal antibodies (NCI-CTCAE 5.0 Grade ≥3).
  • Received hematopoietic stimulating factor treatment within 14 days (≤14 days) before the first dose of the study drug, such as granulocyte colony-stimulating factor, erythropoietin, etc.
  • Central nervous system tumors, , or meningeal are found prior to the first dose of the study drug. Note: Patients with brain metastases are eligible for the study when meeting the following requirements: brain metastases prove to be stable (patients are required to provide the most recent head imaging prior to the first dose, with previous head imaging at least 4 weeks apart, for the investigator to determine whether the brain metastases are stable by comparing the results of the two examinations); any neurological symptoms resulting from brain metastases or their treatment must have resolved or be maintainable to a minimal degree and the symptoms can be clinically determined to be sequelae of the treated lesion; brain metastases treated with must not be treated with steroids for at least 4 weeks prior to the first dose.
  • Treatment with systemic corticosteroids or any other form of systemic within 7 days (≤7 days) prior to the first dose of the study drug. Note: Combination with corticosteroids for the treatment of immune-related adverse events and prophylactic use of anticontras allergy medications are permitted during the study period; patients requiring daily corticosteroid replacement therapy, e.g., 5 to 7.5 milligrams daily doses of prednisone or equivalent doses of hydrocortisone and steroid therapy (topical, intraocular, intranasal inhalation routes only) may be enrolled in this study. Note: Patients with type 1diabetes, vitiligo, psoriasis, hypothyroidism, or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
  • Active disease requiring systemic therapy within the past 2 years or history of autoimmune disease or syndrome requiring systemic steroids/immunosuppressive drugs, e.g., hypophysitis, colitis, hepatitis, nephritis, etc. Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy for renal or pituitary insufficiency) is not considered systemic immunosuppressive therapy. Note: Patients with type I diabetes, vitiligo, psoriasis, hypo- or hyperthyroidism who do not require immunosuppressive therapy are eligible for the study.
  • Has had an allogeneic tissue/solid organ transplant.
  • History of interstitial lung disease or a history of pneumonia that has required oral or intravenous corticosteroids.
  • Symptoms of an active infection requiring intravenous systemic therapy.
  • Positive antibody or positive syphilis spirochete antibody and positive syphilis spirochete antibody titer test result (i.e., active syphilis infection).
  • Presence of active , or tuberculosis. Active hepatitis B and C are defined as follows: active hepatitis B, positive for hepatitis B surface antigen with the hepatitis B virus deoxyribonucleic acid quantification result greater than the ; active hepatitis C, positive for hepatitis C antibody with the hepatitis C virus ribonucleic acid quantification result greater than the ULN.
  • Has (i.e., active) cardiovascular disease. Note: The following cases are observed within 6 months prior to the first dose: heart disease (Class III/IV congestive heart failure or heart block as defined by the ); deep vein thrombosis or pulmonary embolism; myocardial infarction; severe or unstable arrhythmias or angina pectoris; percutaneous coronary intervention, acute coronary syndromes, coronary artery bypass grafting; cerebrovascular accident, , cerebral embolism.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
  • Has known mental illness that would interfere with compliance with the requirements of the trial.
  • Has a history of substance abuse, alcoholism or other addictions.
  • Legal incapacity or legal limitation of capacity.
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Balstilimab

    Balstilimab monotherapy: approximately 147 patients.

    Drug: Balstilimab

  • Experimental
    Balstilimab + Zalifrelimab

    Balstilimab in combination with Zalifrelimab (combination therapy): approximately 30 patients.

    Drug: Balstilimab + Zalifrelimab

Interventions

  • Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody

  • DrugBalstilimab + Zalifrelimab

    Drug pages: Balstilimab · Zalifrelimab

    An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Of Balstilimab Monotherapy Per Independent Review Committee (IRC) Assessment Based Upon Response Evaluation Criteria In Solid Tumours (RECIST) 1.1

    Time frame: 36 months

Secondary outcomes

  1. ORR Of Balstilimab Monotherapy Per Investigator Assessment Based Upon RECIST 1.1

    Time frame: 36 months

  2. Disease Control Rate (DCR) Of Balstilimab Monotherapy Per IRC And Investigator Assessment Based Upon RECIST 1.1

    Time frame: 36 months

  3. Duration of Response (DOR) Of Balstilimab Monotherapy Per IRC And Investigator Assessment Based Upon RECIST 1.1

    Time frame: 36 months

  4. Time to Response (TTR) Of Balstilimab Monotherapy Per IRC And Investigator Assessment Based Upon RECIST 1.1

    Time frame: 36 months

  5. Progression-free Survival (PFS) Of Balstilimab Monotherapy Per IRC And Investigator Assessment Based Upon RECIST 1.1

    Time frame: 36 months

  6. Overall Survival (OS) Of Balstilimab Monotherapy Per IRC And Investigator Assessment Based Upon RECIST 1.1

    Time frame: 48 months

  7. ORR Of Combined Therapy Of Balstilimab And Zalifrelimab Per IRC And Investigator Assessment Based Upon RECIST 1.1

    Time frame: 36 months

  8. DCR Of Combined Therapy Of Balstilimab And Zalifrelimab Per IRC And Investigator Assessment Based Upon RECIST 1.1

    Time frame: 36 months

  9. DOR Of Combined Therapy Of Balstilimab And Zalifrelimab Per IRC And Investigator Assessment Based Upon RECIST 1.1

    Time frame: 36 months

  10. TTR Of Combined Therapy Of Balstilimab And Zalifrelimab Per IRC And Investigator Assessment Based Upon RECIST 1.1

    Time frame: 36 months

  11. PFS Of Combined Therapy Of Balstilimab and Zalifrelimab Per IRC And Investigator Assessment Based Upon RECIST 1.1

    Time frame: 36 months

  12. OS Of Combined Therapy of Balstilimab And Zalifrelimab Per IRC And Investigator Assessment Based Upon RECIST 1.1

    Time frame: 48 months

  13. Peak Plasma Concentration (Cmax) Of Balstilimab And Zalifrelimab

    Time frame: Pre-dose (2 hours prior to dosing [dosing to occur every 6 weeks for up to 24 months/17 cycles or until continued disease progression or intolerable toxicity]), End of Treatment

  14. Time To Peak Plasma Concentration (Tmax) Of Balstilimab And Zalifrelimab

    Time frame: Pre-dose (2 hours prior to dosing [dosing to occur every 6 weeks for up to 24 months/17 cycles or until continued disease progression or intolerable toxicity]), End of Treatment

  15. Half-life (T1/2) Of Balstilimab And Zalifrelimab

    Time frame: Pre-dose (2 hours prior to dosing [dosing to occur every 6 weeks for up to 24 months/17 cycles or until continued disease progression or intolerable toxicity]), End of Treatment

  16. Area Under The Plasma Concentration Versus Time Curve From The Time Of Administration To The Last Measurable Concentration (AUC0-t) Of Balstilimab And Zalifrelimab

    Time frame: Pre-dose (2 hours prior to dosing [dosing to occur every 6 weeks for up to 24 months/17 cycles or until continued disease progression or intolerable toxicity]), End of Treatment

  17. Number Of Participants With Anti-drug Antibodies For Balstilimab And Zalifrelimab

    Time frame: 36 months

  18. Number Of Participants With Treatment-emergent Adverse Events

    Time frame: 48 months

07

Study locations

43 sites
  • Betta Clinical Study Site 4
    Bengbu, Anhui 233004, China
  • Betta Clinical Study Site 2
    Hefei, Anhui 230036, China
  • Betta Clinical Study Site 3
    Hefei, Anhui 230601, China
  • Betta Clinical Study Site 27
    Wuhu, Anhui 241001, China
  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
    Beijing, Beijing 100021, China
  • Betta Clinical Study Site 25
    Beijing, Beijing 100123, China
  • Betta Clinical Study Site 42
    Chongqing, Chongqing 400030, China
  • Betta Clinical Study Site 9
    Fuzhou, Fujian 350014, China
  • Betta Clinical Study Site 22
    Xiamen, Fujian 361003, China
  • Betta Clinical Study Site 41
    Lanzhou, Gansu 730000, China
  • Betta Clinical Study Site 39
    Lanzhou, Gansu 730099, China
  • Betta Clinical Study Site 14
    Huizhou, Guangdong 516001, China
  • Betta Clinical Study Site 18
    Meizhou, Guangdong 514031, China
  • Betta Clinical Study Site 10
    Zhanjiang, Guangdong 524001, China
  • Betta Clinical Study Site 11
    Nanning, Guangxi 530021, China
  • Betta Clinical Study Site 5
    Cangzhou, Hebei 061001, China
  • Betta Clinical Study Site 40
    Harbin, Heilongjiang 150081, China
  • Betta Clinical Study Site 43
    Wuhan, Hubei 430014, China
  • Betta Clinical Study Site 28
    Wuhan, Hubei 430060, China
  • Betta Clinical Study Site 12
    Wuhan, Hubei 430070, China
  • Betta Clinical Study Site 29
    Wuhan, Hubei 430071, China
  • Betta Clinical Study Site 31
    Xiangyang, Hubei 441021, China
  • Betta Clinical Study Site 6
    Changde, Hunan 415003, China
  • Betta Clinical Study Site 36
    Changsha, Hunan 410008, China
  • Betta Clinical Study Site 35
    Changsha, Hunan 410011, China
  • Betta Clinical Study Site 13
    Changsha, Hunan 410013, China
  • Betta Clinical Study Site 21
    Nanjing, Jiangsu 210008, China
  • Betta Clinical Study Site 8
    Nanjing, Jiangsu 210009, China
  • Betta Clinical Study Site 38
    Ganzhou, Jiangxi 341099, China
  • Betta Clinical Study Site 19
    Nanchang, Jiangxi 330006, China
  • Betta Clinical Study Site 20
    Nanchang, Jiangxi 330006, China
  • Betta Clinical Study Site 24
    Shangrao, Jiangxi 334000, China
  • Betta Clinical Study Site 16
    Changchun, Jilin 130021, China
  • Betta Clinical Study Site 15
    Changchun, Jilin 130041, China
  • Betta Clinical Study Site 7
    Dalian, Liaoning 116021, China
  • Betta Clinical Study Site 34
    Shenyang, Liaoning 110001, China
  • Betta Clinical Study Site 17
    Shenyang, Liaoning 110046, China
  • Betta Clinical Study Site 30
    Xi'an, Shaanxi 710061, China
  • Betta Clinical Study Site 23
    Taiyuan, Shanxi 030013, China
  • Betta Clinical Study Site 26
    Tianjin, Tianjin 300000, China
  • Betta Clinical Study Site 37
    Tianjin, Tianjin 300000, China
  • Betta Clinical Study Site 32
    Ürümqi, Xinjiang 830011, China
  • Betta Clinical Study Site 33
    Hangzhou, Zhejiang 310009, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Dec 2024, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2021
First posted
Sep 2, 2021
StartActual
Oct 1, 2021
Primary completionEst.
Dec 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Mar 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05033132
Lead sponsor
Agenus Inc.
Responsible party
Sponsor
First posted
Sep 2, 2021
Start date
Oct 1, 2021
Primary completion
Dec 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Mar 28, 2024

Study contacts

Medical Director
study director · Agenus Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Balstilimab · Zalifrelimab

Start the discussion